Rates of central nervous system (CNS) metastases in patients with advanced non-small cell lung cancer (NSCLC) and somatic EGFR mutations initially treated with …
S Heon, BY Yeap, NI Lindeman, MS Rabin… - Journal of Clinical …, 2011 - ascopubs.org
7607 Background: The impact of tumor genotype and targeted therapies on the control and
development of CNS metastases from NSCLC has not been extensively studied. We …
development of CNS metastases from NSCLC has not been extensively studied. We …
[HTML][HTML] The Role of Brain Radiotherapy before First-Line Afatinib Therapy, Compared to Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non–Small Cell Lung …
HA Jung, S Park, SH Lee, JS Ahn… - Cancer Research and …, 2023 - ncbi.nlm.nih.gov
Purpose Brain metastasis is common in patients with epidermal growth factor receptor
(EGFR)–mutant non–small cell lung cancer (NSCLC) at initial presentation. A previous study …
(EGFR)–mutant non–small cell lung cancer (NSCLC) at initial presentation. A previous study …
The Prognostic Value of Baseline Distant Metastasis in Icotinib-Treated Patients with EGFR-Mutated Stage IV Non-Small Cell Lung Cancer
L Wang, T Shi, L Feng, Z Fan, X Xu, X Zhou… - Cancer Management …, 2021 - Taylor & Francis
Purpose Several studies have revealed the prognostic value distant metastasis in non-small-
cell lung cancer (NSCLC) patients receiving first-line epidermal growth factor receptor …
cell lung cancer (NSCLC) patients receiving first-line epidermal growth factor receptor …
First‐line epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor alone or with whole‐brain radiotherapy for brain metastases in patients with EGFR …
Y Chen, J Yang, X Li, D Hao, X Wu, Y Yang… - Cancer …, 2016 - Wiley Online Library
We proposed to compare the outcomes of first‐line epidermal growth factor receptor–
tyrosine kinase inhibitor (EGFR‐TKI) alone with EGFR‐TKI plus whole‐brain radiotherapy …
tyrosine kinase inhibitor (EGFR‐TKI) alone with EGFR‐TKI plus whole‐brain radiotherapy …
[引用][C] Epidermal Growth Factor Receptor Mutations in Non–Small-Cell Lung Cancer With Brain Metastasis: Can Up-Front Radiation Therapy Be Deferred or Withheld …
L Zhou, L Deng, Y Lu - Journal of Clinical Oncology, 2017 - ascopubs.org
Over the past decade, the advent of tyrosine kinase inhibitors (TKIs) has revolutionized the
management of patients with non–small-cell lung cancer (NSCLC) harboring epidermal …
management of patients with non–small-cell lung cancer (NSCLC) harboring epidermal …
[HTML][HTML] Data from real world to evaluate the efficacy of osimertinib in non-small cell lung cancer patients with central nervous system metastasis
P Xing, Y Mu, X Hao, Y Wang, J Li - Clinical and Translational Oncology, 2019 - Springer
Objectives Central nervous system (CNS) metastases are very common in patients with non-
small-cell lung cancer (NSCLC). We aimed to explore the clinical impact of osimertinib, a …
small-cell lung cancer (NSCLC). We aimed to explore the clinical impact of osimertinib, a …
The retrospective analysis of the frequency of EGFR mutations and the efficacy of gefitinib in NSCLC patients with brain metastasis.
Z Li, J Lu, Y Zhao, H Guo - Journal of Clinical Oncology, 2011 - ascopubs.org
e18065 Background: Some reports have showed that brain metastasis (BM) in the advanced
NSCLC patients has higher EGFR mutations. Gefitinib (TKI) has shown the effectiveness in …
NSCLC patients has higher EGFR mutations. Gefitinib (TKI) has shown the effectiveness in …
[HTML][HTML] A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or …
Background Up to 40% of patients with non-small-cell lung cancer (NSCLC) and epidermal
growth factor receptor (EGFR) mutations treated with EGFR tyrosine kinase inhibitors (TKIs) …
growth factor receptor (EGFR) mutations treated with EGFR tyrosine kinase inhibitors (TKIs) …
[HTML][HTML] Radiotherapy for asymptomatic brain metastasis in epidermal growth factor receptor mutant non-small cell lung cancer without prior tyrosine kinase inhibitors …
SR Liu, B Qiu, LK Chen, F Wang, Y Liang, PQ Cai… - Radiation …, 2015 - Springer
Background Non-small cell lung cancer (NSCLC) with brain metastasis (BM) harboring an
epidermal growth factor receptor (EGFR) mutation shows good response to tyrosine kinase …
epidermal growth factor receptor (EGFR) mutation shows good response to tyrosine kinase …
CNS metastases in non-small-cell lung cancer: current role of EGFR-TKI therapy and future perspectives
LA Berger, H Riesenberg, C Bokemeyer… - Lung Cancer, 2013 - Elsevier
A considerable proportion of non-small-cell lung cancer (NSCLC) patients will develop
central nervous system (CNS) metastases throughout the course of their disease and these …
central nervous system (CNS) metastases throughout the course of their disease and these …